REGISTERED
on 16 Oct 2018
Last Applicant/ Owned by
52428 Jülich
Serial Number
79226526 filed on 20th Jun 2017
Registration Number
5582971 registered on 16th Oct 2018
Correspondent Address
Bldg. 4, Suite 4200
Austin, TX 78759
UNITED STATES
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
PRIAVOID
Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical research, research regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical research, research regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research and development; development of pharmaceutical products; evaluation of results from quality control tests conducted on goods and services in relation to pharmaceutical products; consulting with regard to pharmacology; laboratory research services with regard to pharmaceuticals; research in the field of pharmaceuticals; consulting with regard to pharmaceutical research and development; scientific research in the field of pharmacy; pharmaceutical product evaluation, namely services for the evaluation of the therapeutic effects of pharmaceuticals; research and development services for the pharmaceutical industry; research and development in the field of pharmacy and biotechnology; information technology (IT) consultancy services for pharmaceutical industry and health sector; quality assessment in the nature of quality testing, analysis and evaluation with regard to research in the field of pharmacogenetics; biochemical research; biological research; biological analysis; biological research services; biological development services; biological laboratory services; biochemical analysis; biomedical research; biotechnological research; research regarding biotechnologies; biotechnological research services; scientific research regarding biology; biological research and analysis; research in the field of biotechnology; consulting in the field of biology; consulting in the field of biochemistry; research and development in the field of biochemistry; research and development services in the field of biotechnology
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceuticals for the prevention and treatment of allergies and for the abatement of burns; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceuticals, namely, anti-infectives, immunostimulants; implantable pharmaceuticals namely, biological tissues grafts; serotherapeutic pharmaceuticals for treatment of meningitis and respiratory disorders; pharmaceutical drugs for treatment of Alzheimer's and dementia; medicated throat sprays; medicine for dental purpose; medicine for veterinary purpose, namely, bacteriostats; medicine for intestinal diseases; pharmaceutical preparations for human purposes, namely, for treatment of Alzheimer's and dementia; pharmaceuticals for the treatment of the autonomic nervous system; pharmaceuticals for the treatment of gastrointestinal diseases; pharmaceutical compounds and products for treatment of Alzheimer's and dementia; chemical and pharmaceutical products and preparations for medical purposes, namely, medical diagnostic reagents; antiepileptic pharmaceutical preparations; pharmaceutical compounds and substances for treatment of Alzheimer's and dementia; chemical compounds for pharmaceutical purpose, namely, for the diagnosis of pregnancy; pharmaceutical agents for metabolism; pharmaceutical agents for treatment of the intestines; pharmaceutical compounds for human use, namely, menstrual symptom treatment preparations; synthetic peptides for pharmaceutical purpose for the prevention and treatment of flu; pharmaceutical agents and compounds for the peripheral nervous system; pharmaceutical products for the treatment of infections; pharmaceutical products for the treatment of hyperlipidemias; crystals for therapeutical purpose being pharmaceutical products, namely, mineral preparations; pharmaceutical compounds for the prevention and treatment of metabolic disorder; pharmaceutical compounds for the treatment of kidney diseases; pharmaceutical compounds for the prevention and treatment of metabolic diseases; chemicals for pharmaceutical use, namely, chemical preparations for the diagnosis of pregnancy; pharmaceutical compounds for the treatment of a chemical imbalance; pharmaceutical preparations for the central nervous system; pharmaceutical compounds for the treatment of diabetes; pharmaceutical compounds for the treatment of Parkinson disease; pharmaceutical compounds for the treatment of multiple sclerosis; pharmaceutical compounds and substances for the prevention of cancer; pharmaceutical compounds and substances with analgesic properties; pharmaceutical compounds for the treatment of epilepsy, disorders of the intestines and of the sensory organs; pharmaceutical compounds for the prevention of disorders and diseases of the nervous system; pharmaceutical compounds and substances for the treatment of cancer and cardiovascular diseases; pharmaceutical compounds and substances for use in oncology; pharmaceutical products and substances for the treatment of gastrointestinal diseases; pharmaceutical compounds for the treatment of diseases of the central nervous system (CNS); biological preparations for treatment of neurological disorders; biological compounds for the treatment of cancer; biochemical compounds for the treatment of cancer and for pain treatment; biotechnological compounds for medical purpose, namely, bioactive pharmaceuticals for treatment of Alzheimer's and dementia; diagnostic biomarker reagents for medical purpose; bio-pharmaceuticals for the treatment of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Chemical substances for the production of pharmaceuticals; esters of fatty acids for use in pharmaceuticals; preservatives for pharmaceutical compounds; antimicrobial preservatives for pharmaceutical compounds; chemicals for the preparation being manufacturing and production of pharmaceuticals; antioxidants for the production of pharmaceutical products; chemical compounds for the preparation being manufacturing of pharmaceutical products; esters being viscose chemicals for the production of pharmaceutical products; preservatives for use in the pharmaceutical industry; softening agents being chemical agents for manufacturing for use during the preparation of pharmaceuticals; chemical products for use in the pharmaceutical industry, namely, for use in pharmaceutical manufacturing; active chemical ingredients for the use during the preparation being manufacturing of pharmaceuticals; biochemical compounds for scientific purposes; biochemical products, namely polypeptides for in vitro research applications; biochemical products, namely, chemical reagents for in vitro genetic technology; reagents for use in scientific apparatus for chemical and biological analysis; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79226526
Mark Type
No Service Mark
Attorney Docket Number
No 6509-T50450
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 11th May 2024 | NEW REPRESENTATIVE AT IB RECEIVED |
| 16th Oct 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| 19th Nov 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| 22nd Feb 2019 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 31st Jan 2019 | FINAL DISPOSITION NOTICE SENT TO IB |
| 31st Jan 2019 | FINAL DISPOSITION PROCESSED |
| 16th Jan 2019 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 16th Oct 2018 | REGISTERED-PRINCIPAL REGISTER |
| 31st Jul 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 31st Jul 2018 | PUBLISHED FOR OPPOSITION |